Abstract:Background: Breast cancer is a caomplex disease with high prevalence in women, the molecular mechanisms of which are still unclear at present. Most transcriptomic studies on breast cancer focus on differential expression of each gene between tumor and the adjacent normal tissues, while the other perturbations induced by breast cancer including the gene regulation variations, the changes of gene modules and the pathways, which might be critical to the diagnosis, treatment and prognosis of breast cancer are more or less ignored. Objective: We presented a complete process to study breast cancer from multiple perspectives, including differential expression analysis, constructing gene co-expression networks, modular differential connectivity analysis, differential gene connectivity analysis, gene function enrichment analysis key driver analysis. In addition, we prioritized the related anti-cancer drugs based on enrichment analysis between differential expression genes and drug perturbation signatures. Methods: The RNA expression profiles of 1109 breast cancer tissue and 113 non-tumor tissues were downloaded from The Cancer Genome Atlas (TCGA) database. Differential expression of RNAs was identified using the DESeq2 bioconductor package in R, and gene co-expression networks were constructed using the weighted gene co-expression network analysis (WGCNA). To compare the module changes and gene co-expression variations between tumor and the adjacent normal tissues, modular differential connectivity (MDC) analysis and differential gene connectivity analysis (DGCA) were performed. Results: Top differential genes like MMP11 and COL10A1 were known to be associated with breast cancer. And we found 23 modules in the tumor network had significantly different co-expression patterns. The top differential modules were enriched in Goterms related to breast cancer like MHC protein complex, leukocyte activation, regulation of defense response and so on. In addition, key genes like UBE2T driving the top differential modules were significantly correlated with the patients' survival. Finally, we predicted some potential breast cancer drugs, such as Eribulin, Taxane, Cisplatin and Oxaliplatin. Conclusion: As an indication, this framework might be useful in understanding the molecular pathogenesis of diseases like breast cancer and inferring useful drugs for personalized medication.

Precision Therapeutic Biomarker Identification with Application to the Cancer Genome Project

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Systematic identification of genomic markers of drug sensitivity in cancer cells

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.

Ranking Breast Cancer Drugs and Biomarkers Identification Using Machine Learning and Pharmacogenomics

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine

Identification of Pan-Cancer Biomarkers Based on the Gene Expression Profiles of Cancer Cell Lines

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

SEMCM: A Self-Expressive Matrix Completion Model for Anti-cancer Drug Sensitivity Prediction

Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing

Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment

An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data

Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer.

Epco-36. Integrative Deep-Learning And Pharmacogenomic Profiling Of Malignant Gliomas Using Patient-Derived Tumor Cells